Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + thalidomide
- Development stage
- Phase 2
- Lead developer
- Aston University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of temozolomide, an oral alkylating agent, and thalidomide, an oral immunomodulatory and antiangiogenic agent. Temozolomide damages DNA through alkylation, while thalidomide prevents new blood vessel formation and modulates immune responses. This dual-mechanism approach targets both cancer cells directly and their supporting vasculature, showing particular efficacy in neuroendocrine tumors, glioblastoma multiforme, and melanoma with brain metastases.
02
Targets
CRBN (Cereblon)DNA
Beyond the preview
Go deeper on temozolomide + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + thalidomide.